The authors evaluated the efficiency of Myc-pH-low insertion peptide (pHLIP) in inserting the artificial c-Myc-tag onto the plasma membrane of malignant cells and determined if this engraftment could convert it into a therapeutic target for CAR-T cells or monoclonal antibodies.
[Cancer Letters]